Business News: Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

BRIDGEWATER, N.J., -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego. Presentations will include late-breaking microbiologic data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease who had not started antibiotics.

"We are excited to present both microbiologic and patient-reported respiratory symptoms data from our Phase 3 ARISE trial of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease for the first time in a scientific setting," said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed. "Further, we look forward to sharing data from across our respiratory portfolio, including brensocatib in bronchiectasis and data on the burden of illness of pulmonary hypertension associated with interstitial lung disease, as we advance our efforts to bring forward novel, urgently needed therapies."

Presentations:

• Mini Symposium Session A16, Sunday, May 19, 9:39 AM-9:51 AM PT: Change in Patient Reported Respiratory Symptoms in a Randomized, Double-blind, Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study
• Mini Symposium Session A16 (Late-Breaking Abstract), Sunday, May 19, 9:51 AM-10:03 AM PT: Microbiologic Outcomes From a Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study
• Thematic Poster Session A47, Sunday, May 19, 11:30 AM-1:15 PM PT:
  • Incremental Burden of Pulmonary Hypertension Among Patients with Connective Tissue Disease-related Interstitial Lung Disease in the Real-world Setting
  • Incremental Burden of Pulmonary Hypertension Among Patients with non-Connective Tissue Disease-related Interstitial Lung Disease in the Real-world Setting
• Thematic Poster Session A74, Sunday, May 19, 11:30 AM-1:15 PM PT: Treprostinil Palmitil Conversion Sites in the Lung
• Poster Discussion Session B26, Monday, May 20, 9:15 AM–11:15 AM PT: Incidence and Prevalence of Non-Cystic Fibrosis Bronchiectasis in Japan
• Poster Discussion Session D25, Wednesday, May 22, 8:15 AM–10:15 AM PT
  • A Phase 1 Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment
  • Association Between Exacerbation Burden and Comorbidities Among Patients With Non-Cystic Fibrosis Bronchiectasis Over 1 Year
• Poster Discussion Session D108, Wednesday, May 22, 11:00 AM—1:00 PM PT: Novel Anti-inflammatory and Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib: A Post-hoc Analysis of the WILLOW Trial

About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

More News from Raritan

• Death Investigation at Raritan Public Library of a Somerville Woman The investigation - April 20th, 2024 a Somerville woman with self-inflicted wounds to her arms.
• Acapulco Mexican Restaurant & Bar - Taste of the Day Authentic Mexican Flavors and a DJ for the Weekend Right in Town